Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-10-18

Clinical Trial Update: Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA) [Phase 3]

View source ↗

Summary

Phase 3 trial update on intravenous ferric carboxymaltose for iron deficiency anemia; results completed in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Iron Deficiency Anemia | Phase 3 | Status: COMPLETED | Results posted: 2013-10-18